Aclaris Therapeutics’ (ACRS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.75.

Aclaris Therapeutics Stock Down 0.2%

Shares of NASDAQ:ACRS opened at $4.42 on Wednesday. The stock has a market cap of $478.91 million, a price-to-earnings ratio of -3.20 and a beta of 0.41. The firm’s 50 day moving average price is $2.91 and its 200 day moving average price is $2.24. Aclaris Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. The firm had revenue of $3.30 million during the quarter, compared to the consensus estimate of $1.59 million. On average, equities analysts anticipate that Aclaris Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently modified their holdings of the stock. ProShare Advisors LLC acquired a new position in Aclaris Therapeutics in the 2nd quarter valued at $26,000. AXQ Capital LP acquired a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Aclaris Therapeutics during the 2nd quarter worth approximately $28,000. XTX Topco Ltd acquired a new stake in Aclaris Therapeutics in the second quarter valued at $34,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Aclaris Therapeutics in the second quarter valued at $48,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.